-Alliance enables support for bioreactor systems and related products in the United States-
TOKYO & SOUTHBOROUGH, Mass.-Wednesday 24 February 2021 [ AETOS Wire ]
As a result of the COVID pandemic, the global biopharmaceutical market has been growing at an unprecedented rate, with significant investments being made in diagnostics, vaccine development, and medical devices to test and treat the coronavirus. These investments have driven demand for infrastructure in developing and manufacturing monoclonal antibody drugs and products that require mammalian cell bioreactor technologies.
Since 2007, ICQ Consultants has played an important role in the commissioning and qualification of manufacturing plants in the major life sciences hubs in the United States, including some of the world's largest biomanufacturing facilities. As part of this partnership agreement, Yokogawa will leverage ICQ Consultants’ engineering and laboratory expertise in the biopharmaceutical segment to deploy its new bioprocess technologies in the United States. The first portfolio product, the Advanced Control Bioreactor System BR1000 was recently released on January 8, offering significant performance advantages over existing methods for biologics development.
The automation of manual processes is a rapidly advancing trend in the biopharmaceutical industry. For complete automation of the fed-batch mammalian cell culture process, the control of glucose -- a key nutrient source -- is critical. Through in-line sensing and model predictive control software, and automated feeding, a stable concentration of glucose in bioreactors can be achieved. The BR1000 automates lab-scale mammalian cell culture with highly accurate real-time monitoring and advanced process control.
Michael Bogan, president of ICQ Consultants, commented, "We are very excited to join Yokogawa in this strategic partnership agreement to help facilitate the support of their bioreactor systems and related products throughout the United States. As ICQ Consultants continues to expand operations across the country, we are poised to further develop lasting relationships, which has been a key factor in our ongoing success. I look forward to working with Yokogawa on this unique and collaborative opportunity.”
Hiroshi Nakao, a Yokogawa vice president and head of the company's Life Innovation Business Headquarters, added, "Driven by a clear business vision and recent successes in the life sciences, food, and pharmaceutical sectors, Yokogawa Corporation of America is also turning its attention to biologics development and manufacturing. Alliances with industry experts like ICQ Consultants are vital to gain expertise and penetration in the high growth biopharmaceutical market. ICQ Consultants’ engineering and technical knowledge in drug manufacturing will support our innovative new bioreactor and bioprocess technologies and help position Yokogawa for rapid sales and market leadership in the emerging bio-industrial autonomy sector."
For more information
Advanced Control Bioreactor System BR1000
https://www.yokogawa.com/solutions/products-platforms/life-science/bioreactor/br1000/
About ICQ Consultants
ICQ Consultants partners with leading and emerging biopharma and life sciences companies to help engineering and quality teams proactively anticipate and solve complex commissioning, qualification, and validation challenges. ICQ Consultants’ ultimate goal is to facilitate safe and timely delivery of medications and therapies to patients in need.
Applying a pragmatic approach that is anything but typical, the transparent, data-first communication and project management philosophy ensures strict adherence to continually evolving industry regulations, site-specific requirements, schedules, and budgets. ICQ Consultants gets critical CQV and quality activities done properly so client facilities can focus on saving and improving patient lives.
Since 2007, ICQ Consultants has partnered with the world's largest biopharmaceutical manufacturers and emerging life sciences companies to provide comprehensive commissioning, qualification, and validation services that accelerate the delivery of medications and therapies to patients in need.
ICQ Consultants has also built and maintained a growing database of 500+ skill-assessed CQV professionals, allowing clients to source the right blend of abilities and experience to complement in-house engineering and compliance teams.
About Yokogawa
Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 114 companies spanning 62 countries, generating US$3.7 billion in sales in FY2019. For more information, please visit www.yokogawa.com.
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.
Photos/Multimedia Gallery Available: https://www.businesswire.com/news/home/52375407/en
Contacts
Yokogawa Electric Corporation
Public Relations, Integrated Communications Center
Yokogawa-pr@cs.jp.yokogawa.com
Integrated Commissioning and Qualification Consultants, Corp.
Michael Bogan, President
mbogan@icqconsultants.com
Permalink : https://www.aetoswire.com/news/yokogawa-and-icq-consultants-enter-into-partnership-agreement-for-biopharmaceutical-business/en
No comments:
Post a Comment